STOCK TITAN

Can-Fite BioPharma Ltd. (CANF) EPS by Year

CANF NYSE

Can-Fite BioPharma Ltd. lost $5.97 per diluted share in fiscal year 2025. The table below carries 11 fiscal years, from 2015 to 2025.

FY2025 annual
EPS (Diluted) -$5.97
Source SEC Filings (20-F/6-K) Latest period FY2025, ended Dec 31, 2025 Reported Currency USD

Annual figures, oldest first. Point at a bar to read its period.

CANF EPS (Diluted) by Fiscal Year

Figures are in USD. Each change compares the year with the year before it, and each column links to the filing it was taken from.

MetricFY2520-FFY2420-FFY2320-FFY2220-FFY2120-FFY2020-FFY1920-FFY1820-FFY1720-FFY1620-FFY1520-F
EPS (Diluted)-$5.97-$10.86-$17.92n/m-$30.00-$90.00n/m-$120.00-$420.00-$510.00n/m-$420.00N/AN/A

What diluted earnings per share means

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports.

More Can-Fite BioPharma Ltd. financials

Frequently Asked Questions

Can-Fite BioPharma Ltd. lost $5.97 per diluted share in fiscal year 2025.

Diluted earnings per share divides net income by the share count the company would have if every option and convertible security were exercised, which is the more conservative of the two per-share figures a filer reports. This page lists what Can-Fite BioPharma Ltd. (CANF) reported on that line in every period on record.